APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Drug based on PARP Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Drug based on PARP Inhibitor Market Outlook and Growth Opportunities 2026

Report ID 17397425042 January 2026198 pages

Choose your research edition.

Industry ResearchCancer Drug based on PARP Inhibitor Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Drug based on PARP Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Cancer Drug based on PARP Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Drug based on PARP Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Drug based on PARP Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Drug based on PARP Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Drug based on PARP Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Drug based on PARP Inhibitor market include Clovis Oncology, Zai Lab, AstraZeneca, GSK, Pfizer and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Drug based on PARP Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Drug based on PARP Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Drug based on PARP Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Drug based on PARP Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Drug based on PARP Inhibitor Segment by Company

Clovis Oncology

Zai Lab

AstraZeneca

GSK

Pfizer

Merck & Co

Cancer Drug based on PARP Inhibitor Segment by Type

Talzenna

Rubraca

Zejula

Lynparza

Cancer Drug based on PARP Inhibitor Segment by Application

Ovarian Cancer

Breast Cancer

Other

Cancer Drug based on PARP Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Cancer Drug based on PARP Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cancer Drug based on PARP Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Drug based on PARP Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Drug based on PARP Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drug based on PARP Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Drug based on PARP Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drug based on PARP Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Drug based on PARP Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Drug based on PARP Inhibitor industry.

Chapter 3: Detailed analysis of Cancer Drug based on PARP Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cancer Drug based on PARP Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cancer Drug based on PARP Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Drug based on PARP Inhibitor Industry Trends Table 2. Cancer Drug based on PARP Inhibitor Industry Drivers Table 3. Cancer Drug based on PARP Inhibitor Industry Opportunities and Challenges Table 4. Cancer Drug based on PARP Inhibitor Industry Restraints Table 5. Global Cancer Drug based on PARP Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Drug based on PARP Inhibitor Revenue Share by Company (2021-2026) Table 7. Global Cancer Drug based on PARP Inhibitor Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global Cancer Drug based on PARP Inhibitor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Cancer Drug based on PARP Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cancer Drug based on PARP Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global Cancer Drug based on PARP Inhibitor Company, Product Type & Application Table 13. Global Cancer Drug based on PARP Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Drug based on PARP Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Talzenna Table 18. Significant Companies of Rubraca Table 19. Significant Companies of Zejula Table 20. Significant Companies of Lynparza Table 21. Global Cancer Drug based on PARP Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Cancer Drug based on PARP Inhibitor Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Cancer Drug based on PARP Inhibitor Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Type (2021-2026) Table 25. Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Type (2027-2032) Table 26. Global Cancer Drug based on PARP Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cancer Drug based on PARP Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Cancer Drug based on PARP Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Type (2021-2026) Table 30. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Ovarian Cancer Table 32. Significant Companies of Breast Cancer Table 33. Significant Companies of Other Table 34. Global Cancer Drug based on PARP Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Cancer Drug based on PARP Inhibitor Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Cancer Drug based on PARP Inhibitor Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Application (2021-2026) Table 38. Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Application (2027-2032) Table 39. Global Cancer Drug based on PARP Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Cancer Drug based on PARP Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Cancer Drug based on PARP Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Application (2021-2026) Table 43. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Application (2027-2032) Table 44. Global Cancer Drug based on PARP Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026) & (K Units) Table 46. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2021-2026) Table 47. Global Cancer Drug based on PARP Inhibitor Sales by Region (2027-2032) & (K Units) Table 48. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2027-2032) Table 49. Global Cancer Drug based on PARP Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Cancer Drug based on PARP Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Region (2021-2026) Table 52. Global Cancer Drug based on PARP Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Region (2027-2032) Table 54. Global Cancer Drug based on PARP Inhibitor Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Cancer Drug based on PARP Inhibitor Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Cancer Drug based on PARP Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Cancer Drug based on PARP Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 59. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2026) Table 60. Global Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 61. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2027-2032) Table 62. Global Cancer Drug based on PARP Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Cancer Drug based on PARP Inhibitor Sales Value Market Share by Country (2021-2026) Table 64. Global Cancer Drug based on PARP Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Cancer Drug based on PARP Inhibitor Sales Value Market Share by Country (2027-2032) Table 66. Clovis Oncology Company Information Table 67. Clovis Oncology Business Overview Table 68. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio Table 70. Clovis Oncology Recent Development Table 71. Zai Lab Company Information Table 72. Zai Lab Business Overview Table 73. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio Table 75. Zai Lab Recent Development Table 76. AstraZeneca Company Information Table 77. AstraZeneca Business Overview Table 78. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio Table 80. AstraZeneca Recent Development Table 81. GSK Company Information Table 82. GSK Business Overview Table 83. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. GSK Cancer Drug based on PARP Inhibitor Product Portfolio Table 85. GSK Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio Table 90. Pfizer Recent Development Table 91. Merck & Co Company Information Table 92. Merck & Co Business Overview Table 93. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio Table 95. Merck & Co Recent Development Table 96. Key Raw Materials Table 97. Raw Materials Key Suppliers Table 98. Cancer Drug based on PARP Inhibitor Distributors List Table 99. Cancer Drug based on PARP Inhibitor Customers List Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Cancer Drug based on PARP Inhibitor Product Image Figure 2. Global Cancer Drug based on PARP Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Drug based on PARP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cancer Drug based on PARP Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Cancer Drug based on PARP Inhibitor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Cancer Drug based on PARP Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Talzenna Image Figure 10. Rubraca Image Figure 11. Zejula Image Figure 12. Lynparza Image Figure 13. Global Cancer Drug based on PARP Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Cancer Drug based on PARP Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Type (2021-2032) Figure 16. Global Cancer Drug based on PARP Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Cancer Drug based on PARP Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Type (2021-2032) Figure 19. Ovarian Cancer Image Figure 20. Breast Cancer Image Figure 21. Other Image Figure 22. Global Cancer Drug based on PARP Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Cancer Drug based on PARP Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Application (2021-2032) Figure 25. Global Cancer Drug based on PARP Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Cancer Drug based on PARP Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Application (2021-2032) Figure 28. Global Cancer Drug based on PARP Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Cancer Drug based on PARP Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Cancer Drug based on PARP Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Cancer Drug based on PARP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 33. North America Cancer Drug based on PARP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Cancer Drug based on PARP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Cancer Drug based on PARP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Cancer Drug based on PARP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 39. South America Cancer Drug based on PARP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Cancer Drug based on PARP Inhibitor Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Cancer Drug based on PARP Inhibitor Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Talzenna
  • Rubraca
  • Zejula
  • Lynparza
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • Clovis Oncology
  • Zai Lab
  • AstraZeneca
  • GSK
  • Pfizer
  • Merck & Co

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Drug based on PARP Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global Cancer Drug based on PARP Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global Cancer Drug based on PARP Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cancer Drug based on PARP Inhibitor Market Dynamics
  1. 2.1 Cancer Drug based on PARP Inhibitor Industry Trends
  2. 2.2 Cancer Drug based on PARP Inhibitor Industry Drivers
  3. 2.3 Cancer Drug based on PARP Inhibitor Industry Opportunities and Challenges
  4. 2.4 Cancer Drug based on PARP Inhibitor Industry Restraints
3 Cancer Drug based on PARP Inhibitor Market by Company
  1. 3.1 Global Cancer Drug based on PARP Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Drug based on PARP Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global Cancer Drug based on PARP Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global Cancer Drug based on PARP Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global Cancer Drug based on PARP Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global Cancer Drug based on PARP Inhibitor Company Product Type and Application
  8. 3.8 Global Cancer Drug based on PARP Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cancer Drug based on PARP Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cancer Drug based on PARP Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cancer Drug based on PARP Inhibitor Market by Type
  1. 4.1 Cancer Drug based on PARP Inhibitor Type Introduction
  2. 4.1.1 Talzenna
  3. 4.1.2 Rubraca
  4. 4.1.3 Zejula
  5. 4.1.4 Lynparza
  6. 4.2 Global Cancer Drug based on PARP Inhibitor Sales Volume by Type
  7. 4.2.1 Global Cancer Drug based on PARP Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cancer Drug based on PARP Inhibitor Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Cancer Drug based on PARP Inhibitor Sales Value by Type
  11. 4.3.1 Global Cancer Drug based on PARP Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cancer Drug based on PARP Inhibitor Sales Value by Type (2021-2032)
  13. 4.3.3 Global Cancer Drug based on PARP Inhibitor Sales Value Share by Type (2021-2032)
5 Cancer Drug based on PARP Inhibitor Market by Application
  1. 5.1 Cancer Drug based on PARP Inhibitor Application Introduction
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Other
  5. 5.2 Global Cancer Drug based on PARP Inhibitor Sales Volume by Application
  6. 5.2.1 Global Cancer Drug based on PARP Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Drug based on PARP Inhibitor Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Cancer Drug based on PARP Inhibitor Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Cancer Drug based on PARP Inhibitor Sales Value by Application
  10. 5.3.1 Global Cancer Drug based on PARP Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Drug based on PARP Inhibitor Sales Value by Application (2021-2032)
  12. 5.3.3 Global Cancer Drug based on PARP Inhibitor Sales Value Share by Application (2021-2032)
6 Cancer Drug based on PARP Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global Cancer Drug based on PARP Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global Cancer Drug based on PARP Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cancer Drug based on PARP Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cancer Drug based on PARP Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cancer Drug based on PARP Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global Cancer Drug based on PARP Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cancer Drug based on PARP Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America Cancer Drug based on PARP Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cancer Drug based on PARP Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe Cancer Drug based on PARP Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cancer Drug based on PARP Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cancer Drug based on PARP Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America Cancer Drug based on PARP Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cancer Drug based on PARP Inhibitor Sales Value Share by Country, 2025 VS 2032
7 Cancer Drug based on PARP Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global Cancer Drug based on PARP Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Drug based on PARP Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cancer Drug based on PARP Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global Cancer Drug based on PARP Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cancer Drug based on PARP Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cancer Drug based on PARP Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cancer Drug based on PARP Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cancer Drug based on PARP Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cancer Drug based on PARP Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Clovis Oncology
  2. 8.1.1 Clovis Oncology Company Information
  3. 8.1.2 Clovis Oncology Business Overview
  4. 8.1.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio
  6. 8.1.5 Clovis Oncology Recent Developments
  7. 8.2 Zai Lab
  8. 8.2.1 Zai Lab Company Information
  9. 8.2.2 Zai Lab Business Overview
  10. 8.2.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio
  12. 8.2.5 Zai Lab Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Cancer Drug based on PARP Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GSK Cancer Drug based on PARP Inhibitor Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Merck & Co
  32. 8.6.1 Merck & Co Company Information
  33. 8.6.2 Merck & Co Business Overview
  34. 8.6.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio
  36. 8.6.5 Merck & Co Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Drug based on PARP Inhibitor Value Chain Analysis
  2. 9.1.1 Cancer Drug based on PARP Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Drug based on PARP Inhibitor Sales Mode & Process
  6. 9.2 Cancer Drug based on PARP Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Drug based on PARP Inhibitor Distributors
  9. 9.2.3 Cancer Drug based on PARP Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst